Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Moreno Lanceta, Alazne
  • García Jiménez, Rocío
  • Faneca Farrés, Joana
  • López-Moya, Mario
  • Fornaguera, Cristina
  • García-Villoria, Judith
  • Morales-Ruiz, Manuel
  • Melgar Lesmes, Pedro
  • Borrós, Salvador
  • Jiménez, Wladimiro
Nitric oxide (NO) is a small vasodilator playing a key role in the pathogenesis of portal hypertension. Here, we assessed the potential therapeutic effect of a NO donor targeted to the liver by poly(beta-amino ester) nanoparticles (pBAE NPs) in experimental cirrhosis. Retinol-functionalized NO donor pBAE NPs (Ret pBAE NPs) were synthetized with the aim of actively targeting the liver. Administration of Ret pBAE NPs resulted in uptake and transfection by the liver and spleen. NPs were not found in other organs or the systemic circulation. Treatment with NO donor Ret pBAE NPs (30 mg/ kg body weight) significantly decreased aspartate aminotransferase, lactate dehydrogenase and portal pressure (9.75 ± 0.64 mmHg) compared to control NPs (13.4 ± 0.53 mmHg) in cirrhotic rats. There were no effects on mean arterial pressure and cardiac output. Liver-targeted NO donor NPs reduced collagen fibers and steatosis, activation of hepatic stellate cells and mRNA expression of profibrogenic and proinflammatory genes. Finally, Ret pBAE NPs displayed efficient transfection in human liver slices. Overall, liver-specific NO donor NPs effectively target the liver and mitigated inflammation and portal hypertension in cirrhotic rats. The use of Ret pBAE may prove to be an effective therapeutic strategy to treat advanced liver disease., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Polymeric nanoparticles for liver-targeted pituitary tumor-transforming gene 1 silencing in rats with chronic liver disease

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Casals Mercadal, Gregori
  • Faneca Farrés, Joana
  • Macias-Herranz, Manuel
  • Boix, Loreto
  • Fundora Suarez, Yiliam
  • Morales-Ruiz, Manuel
  • Garcia-Villoria, Judit
  • Fornaguera, Cristina
  • Borrós, Salvador
  • Jiménez, Wladimiro
Pituitary tumor transforming gene 1 (Pttg1) is upregulated in cirrhosis and hepatocarcinoma (HCC). We assessed the therapeutic effect of liver-targeted Pttg1 siRNA Retinol (Ret) pBAE nanoparticles (NPs) to treat these disturbances. Fibrosis was induced in Wistar rats by carbon tetrachloride inhalation and HCC by diethylnitrosamine injection. Ret pBAE NPs accumulated in hepatic tissue, close to zones positive for αSMA staining. Pttg1 interference increased mean arterial pressure, reduced portal hypertension and decreased collagen accumulation and inflammatory infiltrate in fibrotic rats. In HCC rats, Pttg1 silencing reduced liver to body weight ratio and hepatic proliferation and increased hepatic ATP production and serum glucose. This therapy effectively mitigated liver fibrosis and HCC progression in experimental models. The feasibility of this treatment was also demonstrated in human derived hepatic stellate cells and in ex vivo human cirrhotic livers underscoring the therapeutic potential of Pttg1 siRNA Ret pBAE NPs in addressing liver fibrosis and HCC., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Moreno Lanceta, Alazne
  • García Jiménez, Rocío
  • Faneca Farrés, Joana
  • López-Moya, Mario
  • Fornaguera, Cristina
  • García-Villoria, Judith
  • Morales-Ruiz, Manuel
  • Melgar Lesmes, Pedro
  • Borrós, Salvador
  • Jiménez, Wladimiro
Nitric oxide (NO) is a small vasodilator playing a key role in the pathogenesis of portal hypertension. Here, we assessed the potential therapeutic effect of a NO donor targeted to the liver by poly(beta-amino ester) nanoparticles (pBAE NPs) in experimental cirrhosis. Retinol-functionalized NO donor pBAE NPs (Ret pBAE NPs) were synthetized with the aim of actively targeting the liver. Administration of Ret pBAE NPs resulted in uptake and transfection by the liver and spleen. NPs were not found in other organs or the systemic circulation. Treatment with NO donor Ret pBAE NPs (30 mg/ kg body weight) significantly decreased aspartate aminotransferase, lactate dehydrogenase and portal pressure (9.75 ± 0.64 mmHg) compared to control NPs (13.4 ± 0.53 mmHg) in cirrhotic rats. There were no effects on mean arterial pressure and cardiac output. Liver-targeted NO donor NPs reduced collagen fibers and steatosis, activation of hepatic stellate cells and mRNA expression of profibrogenic and proinflammatory genes. Finally, Ret pBAE NPs displayed efficient transfection in human liver slices. Overall, liver-specific NO donor NPs effectively target the liver and mitigated inflammation and portal hypertension in cirrhotic rats. The use of Ret pBAE may prove to be an effective therapeutic strategy to treat advanced liver disease., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polymeric nanoparticles for liver-targeted pituitary tumor-transforming gene 1 silencing in rats with chronic liver disease

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Casals Mercadal, Gregori
  • Faneca Farrés, Joana
  • Macias-Herranz, Manuel
  • Boix, Loreto
  • Fundora Suarez, Yiliam
  • Morales-Ruiz, Manuel
  • Garcia-Villoria, Judit
  • Fornaguera, Cristina
  • Borrós, Salvador
  • Jiménez, Wladimiro
Pituitary tumor transforming gene 1 (Pttg1) is upregulated in cirrhosis and hepatocarcinoma (HCC). We assessed the therapeutic effect of liver-targeted Pttg1 siRNA Retinol (Ret) pBAE nanoparticles (NPs) to treat these disturbances. Fibrosis was induced in Wistar rats by carbon tetrachloride inhalation and HCC by diethylnitrosamine injection. Ret pBAE NPs accumulated in hepatic tissue, close to zones positive for αSMA staining. Pttg1 interference increased mean arterial pressure, reduced portal hypertension and decreased collagen accumulation and inflammatory infiltrate in fibrotic rats. In HCC rats, Pttg1 silencing reduced liver to body weight ratio and hepatic proliferation and increased hepatic ATP production and serum glucose. This therapy effectively mitigated liver fibrosis and HCC progression in experimental models. The feasibility of this treatment was also demonstrated in human derived hepatic stellate cells and in ex vivo human cirrhotic livers underscoring the therapeutic potential of Pttg1 siRNA Ret pBAE NPs in addressing liver fibrosis and HCC., info:eu-repo/semantics/publishedVersion